Max Nisen, Columnist

GlaxoSmithKline Can't Have it All

Investors should realize its ambitions and needs could stretch its balance sheet.

October 25, 2017 at 5:45 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

1508955058_GettyImages-180116715 — Photographer: Matthew Lloyd/Bloomberg via Getty Images

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

GlaxoSmithKline Plc's new leadership is still trying to get its footing.

CEO Emma Walmsley took control in April, and her third earnings call Wednesday morning didn't go especially well. The drugmaker's U.S. depository receipts fell 6 percent after it was less than definitive about maintaining its dividend.